CTOs on the Move

10X Genomics

www.10xgenomics.com

 
10x Genomics meets the critical need for long range, structural and cellular information, with an innovative system that transforms short-read sequencing technologies. Our Chromium™ System supports comprehensive genomics and high-throughput single cell transcriptomics. It enables researchers to discover previously inaccessible genomic information at unprecedented scale, including phased structural variants, phased single nucleotide variants, and dynamic gene expression of individual cells—while leveraging their existing sequencing systems and workflows.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.10xgenomics.com
  • 7068 Koll Center Parkway Suite 401
    Pleasanton, CA USA 94566
  • Phone: 925.401.7300

Executives

Name Title Contact Details
Jason Gao
 Head of Information Security Profile

Funding

10X Genomics raised $55M on 03/17/2016
10X Genomics raised $75M on 04/26/2018
10X Genomics raised $50M on 04/26/2018
10X Genomics raised $35M on 01/07/2019

Similar Companies

Synageva BioPharma

Synageva BioPharma Corp. is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sapphire Biotech

Sapphire Biotech, Inc.`s diagnostic tool is being used to study the company`s enzyme biomarker to detect pancreatic cancer earlier than circulating tumor cells.

Interact Medical

Interact Medical is a South Bend, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IMetrikus

IMetrikus, Inc. is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ViaCyte

ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte`s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates.